|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although human ERG transgene expression or homozygous deletion of <i>Foxo1</i> alone in the mouse prostate failed to promote tumorigenesis, concomitant ERG transgene expression and <i>Foxo1</i> deletion resulted in upregulation of ERG target genes, increased cell proliferation, and formation of high-grade prostatic intraepithelial neoplasia.
|
28986382 |
2017 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results in this case, showing a remarkable absence of truncal mutations in HGPIN lesions bearing the tumor-specific ERG fusion, indicate HGPIN lesions may be relatively stable genetically and argue against a stepwise clonal evolution model of HGPIN to PCa.Prostate 76:1227-1236, 2016.
|
27272561 |
2016 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, we found that a significant fraction of ERG-positive, PTEN-negative HGPIN and intraductal carcinoma (IDC-P) lesions are most likely clonally derived from adjacent PTEN-negative adenocarcinomas, indicating that such PTEN-negative HGPIN and IDC-P lesions arise from, rather than give rise to, the nearby invasive adenocarcinoma.
|
26331372 |
2016 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similar approaches are needed for lesions known as intraductal carcinoma to facilitate better classification of them as true intra-ductal/acinar spread on one hand or as precursor high-grade PIN (cribriform type) on the other hand; a number of such molecular approaches (e.g., coevaluating TMPRSS-ERG fusion and PTEN loss) are already showing excellent promise.
|
26813971 |
2016 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Critically, we find that ERG expression correlates with CHK1 downregulation in human patients and demonstrate that Chk1 heterozygosity promotes the progression of high-grade prostatic intraepithelial neoplasia into prostatic invasive carcinoma in Pten(+) (/-) mice.
|
25653093 |
2015 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERG expression was detected in 11.1% of patients (51 of 461 patients) with isolated HGPIN.
|
24297949 |
2014 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ERG protein expression was detected exclusively in the neoplastic epithelium and was found in 6.8% and 46.3% of high-grade prostatic intraepithelial neoplasia (HGPIN) and localized PCa, respectively.
|
23746715 |
2013 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TMPRSS2:ERG gene fusions, the most common molecular subtype of ETS family gene fusions occur in ~50% of prostate carcinomas (PCas) and ~20% of high-grade prostatic intraepithelial neoplasia (HGPIN) intermingled with adjacent PCa demonstrating identical gene fusions.
|
23399797 |
2013 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 56 (of 59, 94.9%) HGPIN cases with an ERG rearrangements rate ≥1.6% and 5 (of 103, 4.9%) HGPIN cases with an ERG rearrangements rate <1.6% were diagnosed with prostate cancer during repeat biopsy follow-ups (P < 0.001).
|
22696228 |
2012 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We independently evaluated two patient cohorts and observed ERG expression confined to prostate cancer cells and high-grade prostatic intraepithelial neoplasia associated with ERG-positive cancer, as well as vessels and lymphocytes (where ERG has a known biologic role).
|
20651988 |
2010 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma.
|
19396168 |
2009 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concomitance of ERG rearrangement and PTEN deletion was observed in a subset of HGPIN.
|
19407851 |
2009 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a search for possible precursor lesions clonal ERG rearrangements were found both in high grade prostatic intraepithelial neoplasia (PIN) and in atypical in situ epithelial lesions consistent with the diagnosis of low grade PIN.
|
17922029 |
2008 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sixty percent of TMPRSS2-ERG fusion prostate cancer had fusion-negative HGPIN.
|
18519767 |
2008 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TMPRSS2-ERG fusion was present in 48.5% of clinically localized PCA, 30% of hormone naive metastases, 33% of hormone refractory metastases, and in 19% of high grade prostatic intraepithelial neoplasia lesions in intermingling to cancer foci.
|
17527075 |
2007 |
|
High-Grade Prostatic Intraepithelial Neoplasia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate for the first time that the TMPRSS2-ERG fusion gene can be detected in a proportion of HGPIN lesions and that this molecular rearrangement is an early event that may precede chromosome-level alterations in prostate carcinogenesis.
|
17032499 |
2006 |